TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03920059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Description Each capsule contains Mycophenolate mofetil 250 mg. Presentation / Packing Cap 250 mg (white to off white powder, light blue/peach hard gelatin, imprinting with MMF on cap and 250 on body) x 10 x 10's.~Storage Store below 30 degree Celcius.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Description Each capsule contains Mycophenolate mofetil 250 mg. Presentation / Packing Cap 250 mg (white to off white powder, light blue/peach hard gelatin, imprinting with MMF on cap and 250 on body) x 10 x 10's.~Storage Store below 30 degree Celcius.
Study: NCT00244946

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: Lymphocytes collected by standard apheresis technique either prior to or post stem cell mobilization and collection
Study: NCT03973463

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Elastic knee joint movement
Description: Low resistance (7kg and 10kg) elastic band exercise 3 times a week for 12 weeks.Balanced diet reduces oil intake by 1200 calories per day. Maintains 12 weeks.Balanced diet reduces oil intake by 1200 calories per day. Maintains 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Elastic knee joint movement
Description: Low resistance (7kg and 10kg) elastic band exercise 3 times a week for 12 weeks.Balanced diet reduces oil intake by 1200 calories per day. Maintains 12 weeks.Balanced diet reduces oil intake by 1200 calories per day. Maintains 12 weeks.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Elastic knee joint movement
Description: Low resistance (7kg and 10kg) elastic band exercise 3 times a week for 12 weeks.Balanced diet reduces oil intake by 1200 calories per day. Maintains 12 weeks.Balanced diet reduces oil intake by 1200 calories per day. Maintains 12 weeks.
Study: NCT00106691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toremifene 20 mg
Description: The subject takes one dose by mouth of the 20mg Toremifine Citrate tablet once a day for the length of the trial (360 days).
Study: NCT00244946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Study: NCT00106691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The subject takes a placebo tablet identical in appearance to the toremifene 20mg tablet, administered by mouth daily for 360 days.
Study: NCT03071991

Intervention type: PROCEDURE
Intervention: study group
Description: local anesthetic drug will be used

Intervention type: PROCEDURE
Intervention: control group
Description: no local anesthetic drug will be used
Study: NCT03464422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ESTEEM conneCT
Description: The intervention adapts the ESTEEM (Pachankis et al, 2015) intervention to address the multiple-stigma stressors faced by MSM of color, including sexual orientation and racial stigma in a manualized, CBT-based intervention. Approximately thirty participants (divided between two cohorts) will complete ten group sessions will take place at regular times once per week over the course of three months. The groups will be closed, in that no new members will be allowed to join after the first week in order to promote open self-disclosure and trust among group members.
Study: NCT04907435

Intervention type: PROCEDURE
Intervention: simultaneous operations
Description: simultaneous operations

Intervention type: PROCEDURE
Intervention: simultaneous operations
Description: simultaneous operations
Study: NCT03208530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief motivational interview intervention
Description: A brief (\<7minutes) interview by an emergency department clinician to empower patients to formulate and communicate their goals for medical care with patients' outpatient clinicians.
Study: NCT02839902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-085
Description: Omega-3-acid ethyl esters (TAK-085) capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Not treated with omega-3-acid ethyl esters
Description: Not treated with omega-3-acid ethyl esters
Study: NCT01901965

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Neuromuscular electrical stimulation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eccentric training
Study: NCT01376479

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INV21 Low Dose
Description: Inactivated EV71 vaccine containing whole viral particles of EV71 formulated with aluminum hydroxide.
Study: NCT00244946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study: NCT05237414

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: 15 seconds of 2.0 mA direct current applied over the right DLPFC

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active CT
Description: Active memory inhibition CT (i.e., training of memory inhibition specifically for alcohol-related memories).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active CT
Description: Active memory inhibition CT (i.e., training of memory inhibition specifically for alcohol-related memories).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham CT
Description: Sham memory inhibition CT (i.e., participants have to categorize alcoholic and non-alcoholic images but they do not have to inhibit the memories related to these images).
Study: NCT01376479

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INV21 High Dose
Description: Inactivated EV71 vaccine consisting of whole viral particles of EV71 formulated with aluminum hydroxide.
Study: NCT02034539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VADOplex system
Description: intermittent automatic pneumatic compression of the sole of the foot by the VADOplex system
Study: NCT04648995

Intervention type: DEVICE
Group type: OTHER
Intervention: High energy (UltraPulse)
Description: Half of the face that receives low energy, their central base of boxcar scar will be treated with 30mJ, while shoulder of scar will be treated with 60 mJ
Study: NCT00244946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study: NCT01376479

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Phosphate Buffered Saline (PBS)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Phosphate Buffered Saline (PBS)
Study: NCT03353922

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclobenzaprine 10 Mg Oral Tablet
Description: cyclobenzaprine 10 mg tablets
Study: NCT00244946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation (PBSCT)
Study: NCT01318850

Intervention type: OTHER
Group type: OTHER
Intervention: Healthy controls
Description: No intervention
Study: NCT03353922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine 10 Mg Oral Tablet
Description: cyclobenzaprine 10 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: sugar pill

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: sugar pill

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: sugar pill
Study: NCT00868530

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Xyntha
Description: Xyntha for on-demand treatment of bleeding episodes were according to investigator prescription during the 6 months observation period. The recovery assessed by determining the Factor VIII (FVIII) concentration (FVIII:C) levels in individual subjects at the initial and final visits. The dose of Xyntha for recovery assessments is: single 50 IU/kg (±5 IU/kg) IV bolus infusion. All Xyntha administrations occurred in the clinic (hospital).
Study: NCT00346840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol vaginal insert 25 mcg
Description: One hydrogel polymer vaginal insert for up to 24h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol vaginal insert 50 mcg
Description: One hydrogel polymer vaginal insert for up to 24h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol vaginal insert 100 mcg
Description: One hydrogel polymer vaginal insert for up to 24h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol vaginal insert 200 mcg
Description: One hydrogel polymer vaginal insert for up to 24h
Study: NCT03344640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab
Description: AIN457 300 mg subcutaneously for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match AIN457 subcutaneously for 12 weeks
Study: NCT03770494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3405105
Description: Administered orally.
Study: NCT00990145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-322
Study: NCT00987324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taxus stent
Description: Implantation of paclitaxel-eluting stent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SeQuent Please
Description: Dilation with SeQuent Please (paclitaxel-eluting balloon)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Balloon Catheter
Description: Ryuijin, Trek
Study: NCT01130298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Gel 1.62%
Description: 5 grams
Study: NCT02941094

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: needle PLT-805AT
Description: comparing success rate and complications using different needle to US probe angles.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: needle PLT-805AT
Description: comparing success rate and complications using different needle to US probe angles.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: needle PLT-805AT
Description: comparing success rate and complications using different needle to US probe angles.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Xario, Toshiba Tokyo Japan

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Xario, Toshiba Tokyo Japan

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Xario, Toshiba Tokyo Japan
Study: NCT00849446

Intervention type: DEVICE
Intervention: Activity monitor (SenseWear Pro armband)
Description: Activity monitoring during specific physical activities such as walking at different speeds

Intervention type: DEVICE
Intervention: Activity monitor (SenseWear Pro armband)
Description: Activity monitoring during specific physical activities such as walking at different speeds
Study: NCT01065532

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sequent Please Paclitaxel eluting balloon
Description: Sequent Please Paclitaxel eluting balloon
Study: NCT03900897

Intervention type: OTHER
Group type: OTHER
Intervention: Cochlear Implant
Description: Chart review of subjects implanted with a MED-EL cochlear implant under 6 years of age between January 2005 and October 2020.
Study: NCT01190709

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dynamic Compression Plate
Description: we made a longitudinal incision 1 cm lateral to the tibial crest, expose the fracture, and retract the muscles laterally. After determining the length of plate, we used bending instruments to contour the plate to the anatomy then threaded plate holders used to position the plate on the bone. After that we placed the drill guide at the edge of the dynamic compression unit (DCU) portion of the plate hole without applying pressure and tightening of the cortex screws results in dynamic compression. We verified the screw position with a guide wire before insertion and then inserted the locking screw.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Unreamed intramedullary nailing
Description: we inserted the nail, without reaming, across the fracture site, with particular attention being paid to the prevention of over distraction and the achievement of cortical contact of the fracture ends. An upper diameter limit of 10 mm and a nail measuring at least 2 mm less than the diameter measured at the isthmus of the tibia on anteroposterior and lateral radiographs were stipulated.
Study: NCT01065532

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience V everolimus eluting stent
Description: Xience V everolimus eluting stent
Study: NCT04425707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: use of Ivermectin in the treatment of COVID 19 patients, in comparison to and in addition to the standard care of treatment of COVID 19 in Egypt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: use of Ivermectin in the treatment of COVID 19 patients, in comparison to and in addition to the standard care of treatment of COVID 19 in Egypt

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: use of Ivermectin in the treatment of COVID 19 patients, in comparison to and in addition to the standard care of treatment of COVID 19 in Egypt
Study: NCT02953327

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacille Calmette-Guerin
Description: Vaccine against tuberculosis
Study: NCT04648995

Intervention type: DEVICE
Group type: OTHER
Intervention: Low energy (UltraPulse)
Description: Half of the face that receives low energy, their central base of boxcar scar will be treated with 20mJ, while shoulder of scar will be treated with 50 mJ
Study: NCT00806494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: Fesoterodine 4mg for 4 weeks, escalating to fesoterodine 8mg if tolerated
Study: NCT02953327

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: BCG solvent
Description: Simple solvent
Study: NCT03414723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablets~Route of administration: oral
Study: NCT03694743

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2Shape rotary system
Description: root canal preparation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2Shape rotary system
Description: root canal preparation
Study: NCT02616393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesevatinib
Study: NCT04288388

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: massage group
Description: In recent years, in the literature, it is known that many non-pharmacological techniques are applied to reduce the pain of birth in addition to local anesthesia. One of these nonpharmacological methods is the application of pressure to LI4 point on hand with ice.
Study: NCT00019604

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Scan to assess the effects of ablation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Imaging used to assess the effects of this ablative therapy on tumor vascular density.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Physiology based method of imaging disease based on uptake and metabolism of radiopharmaceutical by the tissues.
Study: NCT05947630

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle Foot Orthosis (AFO)
Description: 3D treatment (AFO will be printed) versus traditional made AFO

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knee Ankle Foot Orthosis (KAFO)
Description: 3D treatment (KAFO will be printed) versus traditional made KAFO
Study: NCT03430271

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Intervention
Description: Participants in this arm will complete exercise sessions 1 time per week for 24 weeks. An optional, second PA session will also be offered to PA participants. The exercise sessions will be multimodal and involve walking, lower extremity strengthening exercises, flexibility and balance training.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Healthy Aging Intervention
Description: Participants will attend health education workshops on topics of relevance to older adults. Workshops will be offered weekly in a group setting, and participants will be required to attend biweekly.
Study: NCT00019604

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Description: Radiofrequency ablation uses saline infusion into and out of needle/electrode through a closed system. More energy may be deposited without tissue-charring or gas vaporization.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radionuclide imaging
Description: Imaging following injection of a radioactive material.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound imaging
Description: An ultrasound (e.g. sound waves) is used to identify the lesion and needle placement.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18 (FDG-PET)
Description: FDG PET scans rely on metabolic changes to evaluate response to therapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: gadopentetate dimeglumine
Description: Food and Drug Administration approved contrast agent.
Study: NCT03212885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Electrode that provides electrical stimulation to deep brain structures for relief of Parkinson's Disease symptoms.
Study: NCT01041443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluoro-2-deoxycytidine
Description: Given IV
Study: NCT04111159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Description: Subjects \< 65 years old:Initial dose of 0.4 mg/kg followed by 0.15 mg/kg if needed;Subjects ≥ 65 years old:75% of the dose for subjects \< 65 years old.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Subjects \< 65 years old:Initial dose of 2 mg/kg followed by 0.75 mg/kg if needed;Subjects ≥ 65 years old:75% of the dose for subjects \< 65 years old.
Study: NCT00569166

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Paced breathing (15 min once daily, 6 breaths/min)
Description: Patients practice paced breathing for 15 minutes once daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
Study: NCT03977506

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: On-road driving evaluation
Description: The data assessed during the road test from the two assessment grids (recommendations of the HAS and Test ride for investigation practical fitness to drive) :~road position, vehicle control, track management, safety distances, speed, visual behavior, traffic signs, vehicle overtaking, anticipatory reactions and capabilities adaptation, attentional skills, decision-making, communication with other road users, assessment of specific situations such as insertion on a 2x2 lane, mechanical management and general impressions.
Study: NCT04607291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Health Service
Description: Receive Witness CARES services

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT01593176

Intervention type: PROCEDURE
Intervention: Placement of RSA beads
Description: At the time of surgery sets of up to 9 RSA beads will be implanted on sides of the main fractures lines with the use of the inserter instrument and the image intensifier. In AO/OTA type 33A fractures two sets will be implanted - one in the femoral shaft and one in the distal femoral epiphysis. In AO/OTA type 33C fractures with an extra fracture line through the epiphysis, three sets will be implanted - one in the femoral shaft, one in the main lateral condyle segment and one in the main medial condyle segment. No beads will be planted in comminuted bone fragments. The fracture will then be plated with a LISS plate as it normally would.
Study: NCT01695928

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shockwave therapy
Description: 1000 impulses

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ESWT placebo
Description: 0 impulses, acoustic effect
Study: NCT02079701

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal vaccine
Description: randomization, based upon a random-number (block design) double-blind enrollment sequence. 1:1 ratio.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01041443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetrahydrouridine
Description: Given IV
Study: NCT03818399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUBLOCADE
Description: SUBLOCADE (buprenorphine extended-release) injection is a colorless to amber sterile solution for SC injection designed to deliver buprenorphine at doses of 100 mg or 300 mg at a controlled rate over a one-month period.
Study: NCT02029365

Intervention type: OTHER
Group type: OTHER
Intervention: Autoquestionnary
Description: autoquestionnary completed during the consultation for infertility

Intervention type: OTHER
Group type: OTHER
Intervention: Autoquestionnary
Description: autoquestionnary completed during the consultation for infertility

Intervention type: OTHER
Group type: OTHER
Intervention: semi-structured interview
Description: phone interview
Study: NCT00934791

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus 6-10 mg/day (maintain trough levels of 8-10 ng/mL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Sirolimus 3-5 mg/day (maintain high-performance liquid chromatography (HPLC) blood level 10-15 ng/mL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil 750 mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil 750 mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone tapered to 5 mg/day by day 92

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone tapered to 5 mg/day by day 92